A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis

Atsushi Kuno, Yuzuru Ikehara, Yasuhito Tanaka, Kiyoaki Ito, Atsushi Matsuda, Satoru Sekiya, Shuhei Hige, Michiie Sakamoto, Masayoshi Kage, Masashi Mizokami, Hisashi Narimatsu

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Although liver fibrosis reflects disease severity in chronic hepatitis patients, there has been no simple and accurate system to evaluate the therapeutic effect based on fibrosis. We developed a glycan-based immunoassay, FastLec-Hepa, to fill this unmet need. FastLec-Hepa automatically detects unique fibrosis-related glyco-alteration in serum hyperglycosylated Mac-2 binding protein within 20 min. The serum FastLec-Hepa counts increased with advancing fibrosis and illustrated significant differences in medians between all fibrosis stages. FastLec-Hepa is sufficiently sensitive and quantitative to evaluate the effects of PEG-interferon-α/ribavirin therapy in a short post-therapeutic interval. The obtained fibrosis progression is equivalent to-0.30 stages/year in patients with sustained virological response, and 0.01 stages/year in relapse/nonresponders. Furthermore, long-term follow-up of the severely affected patients found hepatocellular carcinoma developed in patients after therapy whose FastLec-Hepa counts remained above a designated cutoff value. FastLec-Hepa is the only assay currently available for clinically beneficial therapy evaluation through quantitation of disease severity.

Original languageEnglish
Article number1065
JournalScientific Reports
Volume3
DOIs
Publication statusPublished - 2013

Fingerprint

Hepatitis
Fibrosis
Serum
Proteins
Therapeutics
Ribavirin
Therapeutic Uses
Chronic Hepatitis
Immunoassay
Liver Cirrhosis
Interferons
Polysaccharides
Hepatocellular Carcinoma
Carrier Proteins
Recurrence

ASJC Scopus subject areas

  • General

Cite this

A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. / Kuno, Atsushi; Ikehara, Yuzuru; Tanaka, Yasuhito; Ito, Kiyoaki; Matsuda, Atsushi; Sekiya, Satoru; Hige, Shuhei; Sakamoto, Michiie; Kage, Masayoshi; Mizokami, Masashi; Narimatsu, Hisashi.

In: Scientific Reports, Vol. 3, 1065, 2013.

Research output: Contribution to journalArticle

Kuno, Atsushi ; Ikehara, Yuzuru ; Tanaka, Yasuhito ; Ito, Kiyoaki ; Matsuda, Atsushi ; Sekiya, Satoru ; Hige, Shuhei ; Sakamoto, Michiie ; Kage, Masayoshi ; Mizokami, Masashi ; Narimatsu, Hisashi. / A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. In: Scientific Reports. 2013 ; Vol. 3.
@article{2987d3a4691645c0a2324b30aef53a98,
title = "A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis",
abstract = "Although liver fibrosis reflects disease severity in chronic hepatitis patients, there has been no simple and accurate system to evaluate the therapeutic effect based on fibrosis. We developed a glycan-based immunoassay, FastLec-Hepa, to fill this unmet need. FastLec-Hepa automatically detects unique fibrosis-related glyco-alteration in serum hyperglycosylated Mac-2 binding protein within 20 min. The serum FastLec-Hepa counts increased with advancing fibrosis and illustrated significant differences in medians between all fibrosis stages. FastLec-Hepa is sufficiently sensitive and quantitative to evaluate the effects of PEG-interferon-α/ribavirin therapy in a short post-therapeutic interval. The obtained fibrosis progression is equivalent to-0.30 stages/year in patients with sustained virological response, and 0.01 stages/year in relapse/nonresponders. Furthermore, long-term follow-up of the severely affected patients found hepatocellular carcinoma developed in patients after therapy whose FastLec-Hepa counts remained above a designated cutoff value. FastLec-Hepa is the only assay currently available for clinically beneficial therapy evaluation through quantitation of disease severity.",
author = "Atsushi Kuno and Yuzuru Ikehara and Yasuhito Tanaka and Kiyoaki Ito and Atsushi Matsuda and Satoru Sekiya and Shuhei Hige and Michiie Sakamoto and Masayoshi Kage and Masashi Mizokami and Hisashi Narimatsu",
year = "2013",
doi = "10.1038/srep01065",
language = "English",
volume = "3",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis

AU - Kuno, Atsushi

AU - Ikehara, Yuzuru

AU - Tanaka, Yasuhito

AU - Ito, Kiyoaki

AU - Matsuda, Atsushi

AU - Sekiya, Satoru

AU - Hige, Shuhei

AU - Sakamoto, Michiie

AU - Kage, Masayoshi

AU - Mizokami, Masashi

AU - Narimatsu, Hisashi

PY - 2013

Y1 - 2013

N2 - Although liver fibrosis reflects disease severity in chronic hepatitis patients, there has been no simple and accurate system to evaluate the therapeutic effect based on fibrosis. We developed a glycan-based immunoassay, FastLec-Hepa, to fill this unmet need. FastLec-Hepa automatically detects unique fibrosis-related glyco-alteration in serum hyperglycosylated Mac-2 binding protein within 20 min. The serum FastLec-Hepa counts increased with advancing fibrosis and illustrated significant differences in medians between all fibrosis stages. FastLec-Hepa is sufficiently sensitive and quantitative to evaluate the effects of PEG-interferon-α/ribavirin therapy in a short post-therapeutic interval. The obtained fibrosis progression is equivalent to-0.30 stages/year in patients with sustained virological response, and 0.01 stages/year in relapse/nonresponders. Furthermore, long-term follow-up of the severely affected patients found hepatocellular carcinoma developed in patients after therapy whose FastLec-Hepa counts remained above a designated cutoff value. FastLec-Hepa is the only assay currently available for clinically beneficial therapy evaluation through quantitation of disease severity.

AB - Although liver fibrosis reflects disease severity in chronic hepatitis patients, there has been no simple and accurate system to evaluate the therapeutic effect based on fibrosis. We developed a glycan-based immunoassay, FastLec-Hepa, to fill this unmet need. FastLec-Hepa automatically detects unique fibrosis-related glyco-alteration in serum hyperglycosylated Mac-2 binding protein within 20 min. The serum FastLec-Hepa counts increased with advancing fibrosis and illustrated significant differences in medians between all fibrosis stages. FastLec-Hepa is sufficiently sensitive and quantitative to evaluate the effects of PEG-interferon-α/ribavirin therapy in a short post-therapeutic interval. The obtained fibrosis progression is equivalent to-0.30 stages/year in patients with sustained virological response, and 0.01 stages/year in relapse/nonresponders. Furthermore, long-term follow-up of the severely affected patients found hepatocellular carcinoma developed in patients after therapy whose FastLec-Hepa counts remained above a designated cutoff value. FastLec-Hepa is the only assay currently available for clinically beneficial therapy evaluation through quantitation of disease severity.

UR - http://www.scopus.com/inward/record.url?scp=84872716915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872716915&partnerID=8YFLogxK

U2 - 10.1038/srep01065

DO - 10.1038/srep01065

M3 - Article

C2 - 23323209

AN - SCOPUS:84872716915

VL - 3

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 1065

ER -